Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof

A steatohepatitis, non-alcoholic technology, used in disease diagnosis, instrumentation, biomaterial analysis, etc.

Inactive Publication Date: 2009-09-02
METABOLON
View PDF3 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because NAFLD is an insidious disease, existing diagnoses may only be made by needle biopsy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
  • Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
  • Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0153] Correlation of plasma and liver fatty acid composition

[0154] Lipid metabolites expressed as percentage composition of lipid classes were found to be analyzable from blood in relation to hepatic triglyceride content. To determine the potential of blood-based quantities to accurately reflect the fatty acid composition of liver lipid classes, the fatty acid composition of each lipid class was correlated for paired plasma-liver samples derived from normal subjects (from the first set of subjects). The correlation between the fatty acid composition of plasma and liver was excellent for the triglyceride and phosphatidylcholine classes and partially good for the cholesteryl ester class ( figure 2 ). This indicates that plasma fatty acid composition of triglycerides and phosphatidylcholine are accurate indicators of hepatic fatty acid composition of triglycerides and hepatic fatty acid composition of phosphatidylcholine, respectively. Thus, plasma-based fatty acid levels ...

Embodiment 2

[0157] Correlation between hepatic steatosis and liver fatty acid composition

[0158] The first data set was used in this experiment. Liver samples from 49 subjects were assessed for the degree of hepatic steatosis and inflammation. Six subjects were graded as NAFLD and eight subjects were graded as NASH. All other samples were assumed to be normal. use The samples were technically profiled; numerous metabolites were found to be positively or negatively correlated with liver total triglyceride concentrations. In particular, monounsaturated fatty acids are generally positively correlated with steatosis, and essential fatty acids are generally negatively correlated with steatosis. An example of a metabolite that correlates well with total hepatic triglycerides is fatty acid 20:4n6, which is expressed as the percentage of all fatty acids present in the triglycerides ( image 3 ).

[0159] image 3 The relationship between hepatic triglyceride concentration (nmol / g) and t...

Embodiment 3

[0161] Markers of NAFLD and NASH

[0162] The metabolite signatures for NAFLD and NASH in Table 6 were selected based on the observed and / or predicted correlations of the metabolite signatures with liver total triglyceride content. Furthermore, these markers showed some correlation useful in classifying all 16 subjects examined with normal liver function or liver damage.

[0163] Table 6. Blood-Based Lipid Metabolite Markers of Hepatic Steatosis (Mole Percent Based)

[0164] lipid class Positive correlation negative correlation Triglycerides TG14:0 TG15:0 TG14:1n5 TG18:2n6 TG16:0 TG18:3n3 TG18:1n7 TG20:0 TGMUFA TG20:2n6 TT7 TG20:3n6 TGSFA TG20:3n9 TG16:1n7 TG20:4n6 TG20:5n3 TG22:0 TG22:1n9 TG22:2n6 TG22:4n6 TG22:5n3

[0165] TG22:5n6 TG22:6n3 TG24:0 TG24:1n9 TGn3 TGn6 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.

Description

[0001] Cross-references to related applications [0002] This application claims priority to US Provisional Application No. 60 / 836,555, filed August 8, 2006, which is hereby incorporated by reference in its entirety. Background of the invention [0003] Nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease in the United States. NASH is a fatty inflammation of the liver and is a major cause of cirrhosis, fibrosis and liver failure. The disease is progressive, beginning with steatosis or nonalcoholic fatty liver disease (NAFLD), progressing to inflammatory fatty liver (NASH), and progressively leading to cirrhosis and fibrosis. The disease is usually asymptomatic until severe liver injury develops. The diagnosis of NAFLD or NASH requires a liver biopsy because there are no laboratory tests for these two diseases. The diagnosis of NASH requires the presence of fat, inflammation, and centrilobular (zone 3) ballooning with pericellular fibrosis or Magri bo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/92
CPCG01N33/92G01N2800/085G01N2405/02G01N2800/50G01N2800/56
Inventor S·M.·沃特金斯M·M.·维斯特R·A.·贝利
Owner METABOLON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap